HH&L Acquisition Co.
HHLA
New York Stock Exchange10.75
USD
-0.02
- -
CIK
0001824185
ISIN
KYG397141030
CUSIP
G39714103
Return %
Stock
S&P500
1Y
4.57
18.21
3Y
8.59
63.29
5Y
8.59
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Qi Li
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- York House, The Landmark Central Hong Kong
- IPO Date
- Mar 29, 2021
- CIK
- 0001824185
- Website
- hopuhl.com
- Similar Companies
- Business
- HH&L Acquisition Co. (NYSE: HHLA) operates as a blank check company whose primary business is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses; it conducts no significant operations prior to completing an initial business combination. The company primarily targets healthcare or healthcare-related companies in Asian markets, with a particular focus on the Greater China region, or global healthcare or healthcare-related companies with substantial growth potential in Greater China or other Asian markets. Incorporated in 2020 and headquartered in Central, Hong Kong, HH&L Acquisition Co. serves investors seeking exposure to high-growth healthcare opportunities through a special purpose acquisition company structure. In October 2022, HH&L Acquisition Co. announced a definitive business combination agreement with DiaCarta, Ltd., a precision molecular diagnostics company developing oncology and infectious disease tests, valuing DiaCarta at a pre-money equity value of $460 million and targeting completion in the first quarter of 2023 with access to approximately $414 million in trust proceeds assuming no redemptions. The transaction was terminated in June 2023 due to high shareholder redemptions exceeding 84%, leaving insufficient cash post-vote, after which HH&L extended its deadline multiple times up to February 2024. No subsequent merger targets were announced, culminating in the company's full redemption of outstanding Class A ordinary shares and liquidation of its trust in February 2024 at approximately $10.79 per share, marking the end of its operations as a SPAC.